CT1812
CT1812 is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
8 of 8 finished
0.0%
0 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
Clinical Trials (9)
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
Drug Interaction Study of CT1812 in Healthy Volunteers
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
Ascending Dose Study of CT1812 in Healthy Volunteers
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9